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Abstract
Legionella pneumophila is an agent also well known to be frequently responsible for severe community acquired pneumonia. 
Recent studies regarding severe community-acquired pneumonia have shown that Legionella pneumophila is the second 
most common cause of admission to ICU, not far behind pneumococcal pneumonia. The mortality of severe Legionella 
pneumonia is high (30%).
We report two cases of severe respiratory failure due to Legionella pneumophila type 1 treated with non-invasive ventilation 
in the Respiratory Intermediate Care Unit of a Department of Respiratory Medicine with good outcomes.
Severe community-acquired pneumonia is the most common cause of ARDS, and it is the primary reason for Intensive Care 
Unit admission with invasive mechanical ventilation. Delay in ICU admission is probably associated with a poorer outcome. 
The use of non-invasive ventilation in severe community acquired pneumonia is controversial. However, after recent pande-
mics, the number of studies reporting good rates of success for NIV has increased.
Both our patients were managed in a respiratory intermediate care unit, avoiding invasive ventilation and invasive monitoring, 
which lowered costs yet was equally effective in providing a good outcome when compared to intubation in the Intensive Care Unit.
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Introduction
A significant increase in the incidence of 
Legionella pneumophila diseases has been docu-
mented in recent years. The increased incidence 
is global; for example, Germany has seen a signif-
icant increase in community-acquired pneumonia 
(CAP) due to this organism [1]. Legionnaires’ 
disease is a significant health problem in many 
countries, largely because Legionella pneumophila 
pneumonia is a frequent culprit in CAP as well as 
hospital-acquired pneumonia (HAP) [2]. Smoking, 
chronic obstructive lung disease, diabetes, chronic 
corticosteroid therapy and immuno-compromised 
status are known risk factors for Legionnaires’ 
disease [3]. Outcomes were studied in a group 
of 65 patients with severe complications due to 
Legionella pneumophila pneumonia. Six patients 
died (9.2%): four died from septic shock and mul-
ti-organ dysfunction syndrome (MODS); the other 
two died from interstitial pulmonary fibrosis. Other 
severe complications were noted: acute respiratory 
distress syndrome (three cases), renal failure (two 
cases), disseminated intravascular coagulation (two 
cases), septic shock/MODS (two cases), and intersti-
tial pneumonia/pulmonary fibrosis (two cases) [4]. 
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94.3%, lymphocytes 3.60%), glucose 138 mg/dl, 
AST 22 U/L, ALT 17 U/L, GGT 73 U/L, sodium 144 
mEq/l, potassium 3.05 mEq/l, chloride 103 mEq/l, 
calcium 8.15 mg/dl, LDH 407 U/L and C-reactive 
protein 48.22 mg/dl. Chest computed tomography 
showed multifocal consolidations involving the 
left lung with small pleural effusion and ground 
glass opacities associated small pleural effusion 
on the lower right zone (Fig. 1B). Echocardiogra-
phy showed no pericardial effusion. The patient 
continued non invasive ventilation for thirteen 
days (progressively reducing the NIV time of treat-
ment) and was discharged after twenty-five days. 
Respiratory parameters and blood gas analysis are 
shown in Table 1.
The functional measurements performed the 
day before the discharge showed moderate ob-
structive lung function impairment (FVC 74.5% 
Moreover, Legionella pneumophila was found 
co-infecting two cases of H1N1 virus pneumonia 
leading to severe respiratory failure and refractory 
hypoxemia [5]. Legionella pneumophila is an agent 
also well known to be frequently responsible for se-
vere community acquired pneumonia (SCAP) and 
immune-mediated extrapulmonary involvement 
[6]. Because of this, many patients are admitted to 
intensive care unit (ICU), and mechanical ventila-
tion is often required [7].The use of non-invasive 
ventilation (NIV) to treat severe CAP, principally 
in Intensive Care Units, has increased recently [6]. 
We report two cases of severe respiratory failure 
due to Legionella pneumophila type 1 treated with 
non-invasive ventilation in the Respiratory Inter-
mediate Care Unit of a Department of Respiratory 
Medicine with good outcomes.
 Case report
Case 1 
A 76-year-old man with smoking and COPD 
history treated with salmeterol and fluticasone 
twice per day was admitted to the Emergency 
Department for severe pneumonia and respiratory 
failure (oxygen saturation in room air 77%). He 
had yellow-green sputum production, fever, mild 
dyspnoea and a 39° fever. Chest X-ray showed 
dense multilobar consolidations (Fig. 1A). Oxygen 
therapy at 40% flow was administered immediate-
ly. Upon arrival at the Department of Respiratory 
Medicine the following vital signs were obtained: 
respiratory rate 30 breaths/min, and pulse 120 
beats/min. Inspiratory crackles were heard in the 
middle and basal zones of both lungs. Arterial 
blood gas (ABG) analysis revealed paO2 51.7 mm 
Hg, PaCO2 29.8 mm Hg, pH 7.53, HCO3- 26.7, and 
paO2/FIO2 with FIO2 40% was 129. SAPS II was 
23. He was diagnosed with severe respiratory 
failure and started non-invasive ventilation us-
ing a Respironics V60 dedicated NIV platform 
ventilator and full face mask with the following 
settings: IPAP 14 cm H2O, EPAP 10 cm H20, FIO2 
30%. After 1 hour ABG was repeated: paO2 59.1, 
paCO2 31.7, ph 7.482, paO2/FIO2 with FIO2 30% 197 
and respiratory rate 26 m’. The patient continued 
non-invasive ventilation and avoided intubation 
[8]. Specific urinary-test for Legionella pneumo-
phila type 1 was positive. Specific urinary-test for 
Streptococcus pneumoniae was negative. For this 
reason Clarithromycin 500 mg twice a day IV and 
levofloxacin 1000 mg IV once a day were started. 
Laboratory examination on admission revealed: red 
blood cells, 3,900,000; haemoglobin, 12.60 g/dl, 
haematocrit, 37.5%; leukocytes 13970 (neutrophils 
Figure 1 A, B. Chest X-ray and chest computed tomography: pat-
chy multilobar consolidations involving left lung with basal pleural 
effusion and small right basal pleural effusion
A
B
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FEV1 56.7% TI (Tiffeneau index) 66.9 TLC 127.9%, 
RV 138.8% ). At 90th day follow-up and six month 
follow-up the patient continued bronchodilator 
therapy and had a good general condition of health.
Case 2
A 83-year-old woman, suffering from pre- 
-existing diabetes and systemic hypertension, was 
admitted to the Respiratory Department with 
a diagnosis of bilateral pneumonia with respira-
tory failure. She had wet cough, fever (38.5°), and 
dyspnoea. She was in respiratory failure (paO2/ 
/FIO2 ratio 253). Radiological findings of bilateral 
opacities involving lower lung zones were observed 
(Fig. 2A). At admission vital signs were as follows: 
respiratory rate 24 breaths/min, pulse 108 beats/ 
/min, and blood pressure 130/80 mm Hg. Inspirato-
ry crackles were detected at the middle and basal 
left zones and at the basal right zone. Arterial blood 
gas analysis (ABG) demonstrated: paO2 100.2 with 
FIO2 40% paCO2 33.8, pH 7.48, HCO3- 26.2, paO2/ 
/FIO2 ratio 250. The patient was non-invasively 
monitored and continued oxygen therapy at 40% 
flow. The patient was started immediately on 
antibiotic therapy: levofloxacin IV 1000 mg/24 h. 
plus ceftriaxone 2 g/24 h. Twelve hours later the 
clinical picture had worsened: she developed 
tachypnoea (respiratory rate 32 breaths/min), 
tachy cardia (pulse 124 beats/min), hypotension 
(blood pressure 85/50 mm Hg) and severe respira-
tory failure (paO2 69.5 at oxygen flow 50% paCO2 
30.5, pH 7.53 HCO3- 21.6, PaO2/FIO2 ratio 116). 
Infusions of glucocorticosteroids (hydrocortisone 
500 mg IV per day) as well as intravenous colloids 
1000 ml and dopamine at dosage 400 mg/24 h were 
quickly started and continued for 48 hours. 
A
B
Figure 2 A, B. Chest X-ray and chest computed tomography: bilate-
ral consolidations with alveolar bronchogram involving lower lobes 
associated with small bilateral pleural effusions
Table 1. Respiratory parameters and blood gas analysis 
0 h 
Start NIV
1 h 12 h 24 h Day 3 Day 7 Day 10 Day 13 
withdraw
RR 30 27 24 25 22 20 20 18
IPAP 14 16 16 14 10 10 8
EPAP 10 12 12 10 7 6 4
FIO2% 40 30 30 40 35 35 28 21
PaO2 29.8 59.1 59.0 80.7 72.1 75.9 65.1 61.7
PaCO2 51.7 38.2 36.1 35.7 39.4 36.2 32.3 35.2
Ph 7.53 7.48 7.47 7.51 7.43 7.45 7.47 7.46
HCO3 26.7 25.6 25.5 28.9 25.9 24.3 24.8 24.6
P/F 129 197 197 201 206 216 233 294
RR — respiratory rate; IPAP — inspiratory positive airway pressure; EPAP — expiratory positive airway pressure; FIO2% — fraction of inspired oxygen in a gas mixture; 
PaO2 — arterial oxygen pressure; PaCO2 — arterial carbon dioxide pressure; P/F — PaO2/FIO2 ratio; NIV — non-invasive ventilation
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Clarythromycin 500 mg twice a day IV was add-
ed. The patient began non-invasive ventilation with 
a full face mask using a Respironics V 60 dedicated NIV 
platform ventilator with the following settings: IPAP 
16 cmH2O EPAP 10 cmH20 FIO2 40%. ABG control 
after 1 hour showed: paO2 75.9 at oxygen flow 40% 
paCO2 37.5 pH 7.49 HCO3- 22.4 PaO2/FIO2 ratio (P/F) 
190. The patient continued non invasive ventilation 
and avoided intubation [8]. Specific urinary-test for 
Legionella pneumophila type 1 was positive. Specific 
urinary-tests for Streptococcus pneumoniae and IgM 
antibodies against Mycoplasma pneumoniae were 
negative. Laboratory tests on admission were as follows: 
red blood cells 3,850,000, haemoglobin 11.6 g/dL, 
haematocrit 35.2%, leukocytes 17.760 (neutrophils 
95.0% lymphocytes 3.2%), glucose 298 mg/dl, cre-
atinine 0.88 mg/dL, urea 51 mg/dL, AST 33 U/L, 
ALT 19 U/L, GGT 41, sodium 137 mEq/L, potassium 
3.00 mEq/L, chloride 103 mEq/L, calcium 9.52 mg/dL, 
LDH 441 U/L, and C reactive protein 54.90 mg/dL. 
Chest computed tomography showed bilateral patchy 
opacities of lower lobes associated with bilateral 
pleural effusions and ground glass opacities involv-
ing the upper left lobe (Fig. 2B). Respiratory param-
eters and blood gas analysis are shown in Table 2. 
The patient continued non-invasive ventilation for 
twelve days and was discharged after twenty-four 
days. At 90th day follow-up and six month follow-up 
the patient was alive and presented a good general 
condition of health. The two patients have given con-
sent for the publication of material relating to them.
 Discussion 
During the last 35 years Legionella pneumophila 
has become widely recognized as a common cause 
of (CAP) [9]; it is the causal agent of 5% to12% of 
sporadic community-acquired pneumonia cases 
although rates are changing with the use of new 
diagnostic methods [10]. Recent studies regarding 
severe community-acquired pneumonia have shown 
that Legionella pneumophila is the second most 
common cause of admission to ICU, not far behind 
pneumococcal pneumonia [6, 9]. The mortality of 
severe Legionella pneumonia is high (30%).
 Poor outcomes are correlated with pre- 
-existing comorbidities (e.g. cardiac diseases, dia-
betes, acute renal failure). Septic shock, chest X-ray 
extension, severity of respiratory failure (paO2/FIO2 
ratio < 130, paO2 < 60 mm Hg, respiratory rate 
> 30 breaths), and hyponatremia (sodium ≤ 136 
mEq/L) are indicators of poor prognosis [9,10]. The 
term “severe CAP” (SCAP) was created to identify 
the group of patients presenting clinical charac-
teristics described above [11, 12]. Streptococcus 
pneumoniae and Legionella pneumophila are also 
the most common causative organisms both in 
immuno-compromised patients and in non-im-
muno-compromised patients [11, 13]. Legionella 
pneumophila SCAP is linked to several risk fac-
tors such as chronic steroid use, humid weather, 
male sex, smoking, diabetes mellitus, cancer, 
end-stage renal disease, and HIV infection [11]. 
SCAP is the most common cause of ARDS [11]; 
it is the primary reason for Intensive Care Unit 
(ICU) admission [11] with invasive mechanical 
ventilation. Delay in ICU admission is probably 
associated with a poorer outcome [14]. 
The use of corticosteroids in SCAP is contro-
versial. It does not improve clinical outcomes, and 
it prolongs hospitalization [15]. In our case we used 
corticosteroids as a rescue therapy to prevent septic 
shock for a short period. Antibiotic therapy is the 
cornerstone of the treatment, especially in severe Le-
Table 2. Respiratory parameters and blood gas analysis
0 h 
Start NIV
1 h 12 h 24 h Day 3 Day 7 Day 12 
withdraw
RR 30 28 27 27 24 22 22
IPAP 16 16 16 16 12 10
EPAP 10 10 10 8 8 5
FIO2% 50 40 40 40 31 30 25
PaO2 69.5 75.9 77.8 80.3 70.8 74.1 68.9
PaCO2 30.5 37.5 34.8 36.4 38.5 36.6 37.6
Ph 7.53 7.49 7.45 7.47 7.44 7.44 7.44
HCO3 21.6 22.4 22.6 25.3 26.2 26.2 25.2
P/F 116 190 195 201 228 247 287
RR — respiratory rate; IPAP — inspiratory positive airway pressure; EPAP — expiratory positive airway pressure; FIO2% — fraction of inspired oxygen in a gas mixture; PaO2 
— arterial oxygen pressure; PaCO2 — arterial carbon dioxide pressure; P/F — PaO2/FIO2 ratio NIV — non-invasive ventilation
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gionella pneumonia. As previously demonstrated, 
combined therapy improves survival in critically 
ill patients with severe pneumonia. Combined 
treatment with quinolones is the best option for 
severe legionella pneumonia, and it is better than 
monotherapy [16]. Laboratory and experimental 
data suggest that both fluoroquinolones and ne-
wer macrolides are superior to erythromycin, and 
recent studies suggest that levofloxacin should be 
considered the drug of choice for the treatment of 
mild to moderate Legionella pneumonia. Traditio-
nal combinations do not always work. Rifampin 
was a very active drug against Legionella, but the 
organism is showing increased resistance [16]. 
Therefore, we used a combined treatment with 
levofloxacin and clarithromycin, a combination 
uncommonly used [16]. This combination therapy 
proved effective in our two cases.
The use of non-invasive ventilation (NIV) in 
SCAP is controversial. The risks of NIV failure in 
these patients are not yet clear [17]; however, after 
recent pandemics, the number of studies reporting 
good rates of success for NIV has increased [18]. 
The use of NIV in Legionella pneumophila was de-
scribed in only one case managed in a medical ICU; 
it avoided invasive mechanical ventilation and 
had a good outcome [19]. The two cases presented 
here had SAPS II lower than 34 and PaO2/FIO2 after 
1 hour greater than 175, which are predictors of 
NIV success [8, 20]. Both patients were managed 
in the respiratory intermediate care unit [21], 
avoiding invasive ventilation and invasive moni-
toring, using less expensive but equally effective 
strategies. In severe pneumonia the continuous 
monitoring of the patients’ status is crucial for 
optimal outcome. We underline that the PaO2/FIO2 
ratio improved rapidly and continuously. We stress 
that no other organ failure complicated the hospital 
course of our two patients.
Monitoring other organ systems is of paramo-
unt importance. We are aware of the limitations 
of this report. More specific parameters are ne-
eded to identify CAP severity and its outcome. 
Studies are required to identify predictors of 
success or failure of non-invasive ventilation, 
which would allow safe management of SCAP 
outside the ICU. 
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
The author would like to thank Dr. Cornelius 
Barlascini for reviewing the manuscript.
Conflict of interest
The Authors declare no conflict of interest.
References: 
1. Carratala’ J., Garcia-Vidal C. An update on Legionella Curr. Opin. 
Infect. Dis. 2010; 23: 152–157.
2. Diederen B.M. Legionella spp and Legionnaires’ disease. J. Infect. 
2008; 56: 1–12.
3. Biegel F., Jurgens M., Filik L. et al. Severe legionella pneumophila 
pneumonia following Infliximab therapy in a patient with Crohn’s 
disease. Inflamm. Bowel. Dis. 15: 1240–1244.
4. Takayanagi N., Ishiguro T., Matsushita A. et al. Severe complications 
and their outcomes in 65 patients with Legionella pneumonia. Nihon. 
Kokyuki. Gakkai. Zasshi. 2009; 47: 58–68.
5. Iannuzzi M., De Robertis E., Piazza O., Rispoli F., Servillo G., Tufano 
R. Respiratory failure presenting in H1N1 influenza with Legionnaires 
disease; two case reports. J. Med. Case. Rep. 2011; 5: 520.
6. De Pascale G., Bello G., Tumbarello M., Antonelli M. Severe pneumo-
nia in intensive care: cause, diagnosis, treatment, and management: 
a review of the literature. Curr. Opin. Pulm. Med. 2012; 18: 213–221.
7. Falco V., Fernandez de Sevilla T., Alegre J., Ferrer A., Martinez Vazquez 
J.M. Legionella pneumophila: a cause of severe community-acquired 
pneumonia. Chest 1991; 100: 1007–1011.
8. Antonelli M., Conti G., Esquinas A. et al. A multiple-center sur-
vey on the use in clinical practice of non invasive ventilation as 
a first-line intervention for acute respiratory distress syndrome 
Crit. Care Med. 2007; 35: 18–25.
9. El-Ebiary M., Sarmiento X., Torres A. et al. Prognostic factors of severe 
Legionella Pneumonia requiring admission to ICU. Am. J. Resp. Crit. 
Care Med. 1997; 156: 1467–1472.
10.  Benito J.R., Montejo J.M., Cancelo L. et al. Neumonia comunitaria por 
Legionella pneumophila serogruppo1.Estudio de 97 casos. Enferm. 
Infec. Microbiol. Clin. 2003; 21: 394–400.
11. Restrepo M.I., Anzueto A. Severe community-acquired pneumonia. 
Infect. Dis. Clin. N. Am. 2009; 23: 503–520.
12. Brown S.M., Dean N.C. Defining severe pneumonia. Clin. Chest Med. 
2011; 32: 469–479. 
13. De Sousa I.J., Dominguez A., Manzur A. et al. Community-acquired 
pneumonia in immunocompromised older patients: incidence, causative 
organisms and outcome. Clin.Microbiol. Infect. 2013; 19: 187–192. 
14. Restrepo M.I., Mortensen E., Rello J., Brody J., Anzueto A. Late admis-
sion to the ICU in patients with community-acquired pneumonia is 
associated with higher mortality. Chest 2010; 137: 552–557.
15. Polverino E., Cilloniz C., Dambrava P., Gabarrus A., Ferrer M., Agusti C. 
Systemic corticosteroids for community acquired pneumonia: reasons 
for use and lack of benefit on outcome. Respirol. 2013; 18: 263–271.
16. Rello J., Gattarello S., Souto J. et al.Community-acquired Legionella 
pneumonia in the intensive care unit: impact on survival of com-
bined antibiotic therapy Med. Intensiva 2012; dx.doi.org/10.1016/ 
/J.Medin.2012.05.10.
17. Carrillo A., Gonzales-Diaz G., Ferrer M. et al. Non-invasive ventilation 
in community-acquired pneumonia and severe respiratory failure. 
Intens. Care Med. 2012; 38: 458–466.
18. Winck J.C., Goncalves M. H1N1 infection and acute respiratory fail-
ure: can we give non-invasive ventilation a chance? Rev. Port. Pneu-
mol. 2010; 16: 907–911.
19. Eryuksel E., Karakurt S., Celikel T. Non-invasive positive pressure 
ventilation for a severe legionella pneumonia case. Tuberkul. Toraks. 
Derg. 2009; 57: 348–351.
20. Conti G., Costa R. Noninvasive ventilation in patients with hypox-
emic, non hypercapnic acute respiratory failure. Clin. Pulm. Med. 
2011; 18: 83–87.
21. Corrado A., Roussos C., Ambrosino N. et al. Respiratory intermediate 
care units: a European survey. Eur. Resp. J. 2002; 20: 1343–1350.
